logo-loader
viewe-Therapeutics plc

e-Therapeutics director buys shares with fees

The group said he subscribed for 36,917 new shares at 7.45p each worth around £2,750.

empt_boardroom,_sized_586cb24d0f08a.png
In October, Professor Jones entered into a binding contractual arrangement where he agreed, with effect from October 1 last year to invest 50% of his annual non-executive director fees net of tax in new e-Therapeutics' stock

Non-exec director at drug discovery firm e-Therapeutics plc (LON:ETX) Professor Trevor Jones has bought shares in the company instead of taking part of his fees.

The group said he subscribed for  36,917 new shares at 7.45p each worth around £2,750.

In October, Professor Jones entered into a binding contractual arrangement where he agreed, with effect from October 1 last year to invest 50% of his annual non-executive director fees net of tax in new  e-Therapeutics' stock.

He will now be interested in around 107,497 shares, or around 0.04% of the capital.

Quick facts: e-Therapeutics plc

Price: 3.25 GBX

AIM:ETX
Market: AIM
Market Cap: £8.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Holding(s) in Company

1 month, 1 day ago

Holding(s) in Company

on 10/29/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Half-year Report

on 10/07/2019

Holding(s) in Company

on 09/17/2019

2 min read